The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)
 

Editor

Share

Personal info

View

Links

Table of contents

About

Terms

 

Jawed Fareed

Loyola University Chicago

Department of Pathology and Pharmacology

2160 S. First Avenue

Maywood

USA

[email]@lumc.edu

Name/email consistency: high

 
 
 
 
 
 
 

Affiliations

  • Loyola University Chicago, Department of Pathology and Pharmacology, 2160 S. First Avenue, Maywood, USA. 2013
  • Departments of Pathology and Pharmacology, Loyola University Medical Center, Maywood, Illinois 60153; email:. 2001 - 2012

References

  1. Metabolic differences of current thienopyridine antiplatelet agents. Fareed, J., Jeske, W., Thethi, I. Expert. Opin. Drug. Metab. Toxicol (2013) [Pubmed]
  2. Old versus new oral anticoagulants: focus on pharmacology. Fareed, J., Thethi, I., Hoppensteadt, D. Annu. Rev. Pharmacol. Toxicol. (2012) [Pubmed]
  3. Differentiation of parenteral anticoagulants in the prevention and treatment of venous thromboembolism. Fareed, J., Adiguzel, C., Thethi, I. Thromb. J (2011) [Pubmed]
  4. Apixaban to prevent venous thromboembolism after knee replacement. Fareed, J., Hull, R. Lancet (2010) [Pubmed]
  5. Are all low molecular weight heparins equivalent in the management of venous thromboembolism? Fareed, J., Jeske, W., Fareed, D., Clark, M., Wahi, R., Adiguzel, C., Hoppensteadt, D. Clin. Appl. Thromb. Hemost. (2008) [Pubmed]
  6. Survival of heparins, oral anticoagulants, and aspirin after the year 2010. Fareed, J., Hoppensteadt, D.A., Fareed, D., Demir, M., Wahi, R., Clarke, M., Adiguzel, C., Bick, R. Semin. Thromb. Hemost. (2008) [Pubmed]
  7. Changing trends in anti-coagulant therapies. Are heparins and oral anti-coagulants challenged? Fareed, J., Iqbal, O., Cunanan, J., Demir, M., Wahi, R., Clarke, M., Adiguzel, C., Bick, R. Int. Angiol (2008) [Pubmed]
  8. Update on the clinical applications of argatroban. Fareed, J., Jeske, W.P., Hoppensteadt, D.A., Walenga, J.M. Future. Cardiol (2006) [Pubmed]
  9. Development of generic low molecular weight heparins: a perspective. Fareed, J., Leong, W., Hoppensteadt, D.A., Jeske, W.P., Walenga, J., Bick, R.L. Hematol. Oncol. Clin. North Am. (2005) [Pubmed]
  10. Biochemical and pharmacologic heterogeneity in low molecular weight heparins. Impact on the therapeutic profile. Fareed, J., Hoppensteadt, D., Schultz, C., Ma, Q., Kujawski, M.F., Neville, B., Messmore, H. Curr. Pharm. Des. (2004) [Pubmed]
  11. Differentiation of low-molecular-weight heparins: impact on the future of the management of thrombosis. Fareed, J., Ma, Q., Florian, M., Maddineni, J., Iqbal, O., Hoppensteadt, D.A., Bick, R.L. Semin. Thromb. Hemost. (2004) [Pubmed]
  12. Small-molecule direct antithrombins: argatroban. Fareed, J., Jeske, W.P. Best. Pract. Res. Clin. Haematol (2004) [Pubmed]
  13. Blood levels of nitric oxide, C-reactive protein, and tumor necrosis factor-alpha are upregulated in patients with malignancy-associated hypercoagulable state: pathophysiologic implications. Fareed, D., Iqbal, O., Tobu, M., Hoppensteadt, D.A., Fareed, J. Clin. Appl. Thromb. Hemost. (2004) [Pubmed]
  14. Generic low-molecular-weight heparins: some practical considerations. Fareed, J., Leong, W.L., Hoppensteadt, D.A., Jeske, W.P., Walenga, J., Wahi, R., Bick, R.L. Semin. Thromb. Hemost. (2004) [Pubmed]
  15. Management of thrombotic and cardiovascular disorders in the new millenium. Fareed, J., Hoppensteadt, D.A., Bick, R.L. Clin. Appl. Thromb. Hemost. (2003) [Pubmed]
  16. Pharmacodynamic and pharmacokinetic properties of enoxaparin : implications for clinical practice. Fareed, J., Hoppensteadt, D., Walenga, J., Iqbal, O., Ma, Q., Jeske, W., Sheikh, T. Clin. Pharmacokinet (2003) [Pubmed]
  17. Practical issues in the development of argatroban: a perspective. Fareed, J., Hoppensteadt, D., Iqbal, O., Tobu, M., Lewis, B.E. Pathophysiol. Haemost. Thromb. (2002) [Pubmed]
  18. Antithrombin and anti-Xa agents in the control of thrombogenesis. Fareed, J., Shaikh, T., Hoppensteadt, D.A. Pharmazie (2001) [Pubmed]
 
WikiGenes - Universities